GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cutera Inc (NAS:CUTR) » Definitions » Altman Z-Score

Cutera (Cutera) Altman Z-Score

: -0.41 (As of Today)
View and export this data going back to 2004. Start your Free Trial

The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.

Warning Sign:

Altman Z-score of -0.4 is in distress zone. This implies bankruptcy possibility in the next two years.

Cutera has a Altman Z-Score of -0.41, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

The zones of discrimination were as such:

When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.

The historical rank and industry rank for Cutera's Altman Z-Score or its related term are showing as below:

CUTR' s Altman Z-Score Range Over the Past 10 Years
Min: -0.4   Med: 4.58   Max: 12.43
Current: -0.4

During the past 13 years, Cutera's highest Altman Z-Score was 12.43. The lowest was -0.40. And the median was 4.58.


Cutera Altman Z-Score Historical Data

The historical data trend for Cutera's Altman Z-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cutera Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Altman Z-Score
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.14 5.72 3.75 3.36 1.40

Cutera Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Altman Z-Score Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.65 1.40 0.73 0.47 -0.32

Competitive Comparison

For the Medical Devices subindustry, Cutera's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cutera Altman Z-Score Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Cutera's Altman Z-Score distribution charts can be found below:

* The bar in red indicates where Cutera's Altman Z-Score falls into.



Cutera Altman Z-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Cutera's Altman Z-Score for today is calculated with this formula:

Z=1.2*X1+1.4*X2+3.3*X3+0.6*X4+1.0*X5
=1.2*0.5383+1.4*-0.6052+3.3*-0.2485+0.6*0.0745+1.0*0.5661
=-0.41

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.

Trailing Twelve Months (TTM) ended in Sep. 2023:
Total Assets was $406.6 Mil.
Total Current Assets was $311.3 Mil.
Total Current Liabilities was $92.4 Mil.
Retained Earnings was $-246.1 Mil.
Pre-Tax Income was -44.107 + -32.952 + -27.776 + -7.024 = $-111.9 Mil.
Interest Expense was -2.939 + -2.958 + -2.939 + -1.992 = $-10.8 Mil.
Revenue was 46.478 + 61.825 + 54.526 + 67.353 = $230.2 Mil.
Market Cap (Today) was $38.9 Mil.
Total Liabilities was $522.7 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(311.307 - 92.406)/406.633
=0.5383

X2=Retained Earnings/Total Assets
=-246.113/406.633
=-0.6052

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-111.859 - -10.828)/406.633
=-0.2485

X4=Market Value Equity/Book Value of Total Liabilities
=Market Cap/Total Liabilities
=38.925/522.718
=0.0745

X5=Revenue/Total Assets
=230.182/406.633
=0.5661

The zones of discrimination were as such:

Distress Zones - 1.81 < Grey Zones < 2.99 - Safe Zones

Cutera has a Altman Z-Score of -0.41 indicating it is in Distress Zones.

Study by Altman found that companies that are in Distress Zone have more than 80% of chances of bankruptcy in two years.


Cutera  (NAS:CUTR) Altman Z-Score Explanation

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.

X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.

Read more about Altman Z-Score and the original research.


Be Aware

Altman Z-Score does not apply to financial companies.


Cutera Altman Z-Score Related Terms

Thank you for viewing the detailed overview of Cutera's Altman Z-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Cutera (Cutera) Business Description

Traded in Other Exchanges
Address
3240 Bayshore Boulevard, Brisbane, CA, USA, 94005
Cutera Inc is a medical device company. It specializes in the design, development, manufacture, marketing and servicing of laser and other energy based aesthetics systems for practitioners internationally. Its products include enlighten, excel HR, excel V, Xeo and Trusculpt 3D among others. The company markets and sells its products under the trademarks such as Cutera, Acutip, Coolglide, Enlighten, Excel HR, Excel V, Genesis plus, Pico-genesis, Titan, Trusculpt, and Xeo among others. It derives the majority of its revenue from the United States geographic segment.
Executives
Taylor C. Harris director 6035 STONERIDGE DRIVE, PLEASANTON CA 94588
Stuart Drummond officer: Interim Chief Financial Office C/O CUTERA, INC., 3240 BAYSHORE BLVD., BRISBANE CA 94005
Jeffrey S Jones officer: Chief Operating Officer C/O RELIANT TECHNOLOGIES, INC., 464 ELLIS STREET, MOUNTAIN VIEW CA 94043
Kevin J Cameron director C/O KERYX BIOPHARMACEUTICALS, INC., 750 LEXINGTON AVENUE, NEW YORK NY 10022
Nicholas Sheridan Lewin director 3 WEST 57TH ST., 8TH FLOOR, NEW YORK NY 10019
Keith J Sullivan director C/O RELIANT TECHNOLOGIES, INC., 464 ELLIS STREET, MOUNTAIN VIEW CA 94043
David H Mowry director, officer: Chief Executive Officer 9775 TOLEDO, IRVINE CA 92618
Rohan Seth officer: Chief Financial Officer C/O CUTERA, INC., 3240 BAYSHORE BLVD., BRISBANE CA 94005
Timothy J Oshea director C/O CUTERA, INC., 3240 BAYSHORE BLVD., BRISBANE CA 94005
Juliane Park director C/O CUTERA, INC., 3240 BAYSHORE BLVD., BRISBANE CA 94005
Janet D. Widmann director 1411 E. MISSION AVENUE, SPOKANE WA 99202
J Daniel Plants director ONE EMBARCADERO CENTER, SUITE 1140, SAN FRANCISCO CA 94111
Katherine S Zanotti director 431 E 9TH STREET, HINSDALE IL 60521
Joseph E Whitters director
Sheila Hopkins director C/O WARNACO INC, 90 PARK AVENUE, NEW YORK NY 10016

Cutera (Cutera) Headlines

From GuruFocus